<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="34965">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01656720</url>
  </required_header>
  <id_info>
    <org_study_id>NRL001-01/2011 (SEFI)</org_study_id>
    <nct_id>NCT01656720</nct_id>
  </id_info>
  <brief_title>A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety and Tolerability of Locally Applied NRL001 Over an 8 Week Treatment Period</brief_title>
  <official_title>A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety and Tolerability of Locally Applied NRL001 Over an 8 Week Treatment Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norgine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Norgine</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and efficacy of NRL001 in
      the treatment of faecal incontinence, compared against placebo
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Evaluate the efficacy of NRL001 in faecal incontinence by assessing the improvement of the incontinence status after 4 weeks of treatment compared to baseline by means of the Wexner score</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To provide data on the efficacy of NRL001 in patients with faecal incontinence over an 8 week treatment period</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To provide preliminary data on the safety and tolerability of NRL001 (5mg, 7.5mg and 10mg) over an 8 week treatment period compared to placebo</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the population pharmacokinetics and to establish any pharmacokinetic/pharmacodynamic relationship with adverse events</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the dose-response relationship in order to identify the appropriate dose(s) of NRL001 for future studies</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of treatment according to the patient's Faecal Incontinence Quality of Life questionnaire at 4 and 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of treatment according to the Vaizey score at 4 and 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">580</enrollment>
  <condition>Faecal Incontinence</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 2g Suppository</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NRL001 5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5mg NRL001 in a 2g suppository</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NRL001 7.5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7.5mg NRL001 in a 2g suppository</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NRL001 10mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10mg NRL001 in a 2g suppository</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1R, 2S-methoxamine hydrochloride</intervention_name>
    <arm_group_label>NRL001 5mg</arm_group_label>
    <arm_group_label>NRL001 7.5mg</arm_group_label>
    <arm_group_label>NRL001 10mg</arm_group_label>
    <other_name>NRL001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  An ultrasound assessment of the internal anal sphincter within the previous 12 months
             confirming an intact circular internal sphincter with minimal scars (maximum 60
             degrees scarring circumferentially).

          -  Diagnosis of faecal incontinence with a Wexner score of 8 - 20 inclusive at Visit 1 -
             Screening Visit.

          -  Historical clinical evidence (past 6 months prior to Visit 1 - Screening Visit) of
             faecal incontinence episodes (solids, liquid, gas or mucus).

          -  Greater than or equal to two faecal incontinence episodes (solids, liquid, gas or
             mucus) per week during the 4 week historical period prior to Visit 1 - Screening
             Visit.

          -  Able and willing to receive rectal examinations and treatments.

          -  Patients must be aged &gt;18 without significant acute or uncontrolled chronic disease.

          -  Patients must understand the purpose and risks of the study and be able to provide
             written informed consent and willing, able and competent to complete the entire study
             and comply with study instructions as defined in the protocol.

          -  Female patients must be postmenopausal (for at least one year and confirmed by serum
             FSH at screening), or surgically sterile, practicing true sexual abstinence, or using
             Investigator-approved methods of contraception throughout the study until after the
             post study physical examination and have a negative pregnancy test at screening.

          -  Sexually active male patients must use condoms with their partners throughout the
             study and for 90 days after completion of the study in addition to their partner's
             normal mode of contraception.

          -  Male patients must not donate sperm during the study and for 90 days after the
             completion of the study.

          -  Patients taking any continuous medication need to have been on a stable regimen for
             at least 1 month prior to Visit 1 - Screening Visit.

        Exclusion Criteria:

          -  External anal sphincter disruption related to faecal incontinence caused by trauma.

          -  Patients with complicating gastrointestinal (GI) disease including those with
             inflammatory bowel diseases, patients that have received radiotherapy or surgery for
             anal cancer, patients with rectal prolapse, transanal surgery.

          -  Relevant history of or presence of any significant or uncontrolled cardiovascular
             risk including:

               1. Systolic &gt; 160mmHg or Diastolic &gt; 100mmHg. Patients on a stable regimen for &gt; 3
                  months with controlled hypertension prior to Visit 1 - Screening Visit (Systolic
                  &lt; 140mmHg or Diastolic &lt; 90mmHg) can be included.

               2. Abnormal 24 hour Screening Holter: corrected QT interval (QTcf) prolongation
                  with cut-off values of &gt;460 ms for females and &gt;430 ms for males, acute
                  arrhythmia, nocturnal bradycardia with heart rate (HR) &lt; 40bpm, atrial
                  fibrillation, AV block Type II and III, Sick Sinus Syndrome, vasovagal syncope.

               3. Fixed cardiac output states (severe aortic stenosis (AS), hypertrophic
                  obstructive cardiomyopathy (HOCM).

               4. Significant mitral regurgitation (MR).

               5. Cardiac failure (New York Heart Association (NYHA) stage II-IV).

          -  Severe or uncontrolled asthma or chronic obstructive pulmonary disease determined by
             clinical history, physical examination, lung function tests or exercise tolerance

          -  Chronic liver disease (e.g. liver cirrhosis, chronic hepatitis, severe hepatic
             insufficiency).

          -  Vascular claudication after &lt;50 metres walking distance.

          -  Severe renal impairment defined as glomerular filtration rate (GFR) ≤ 30 ml/min,
             uncontrolled and reno-vascular end stage renal disease.

          -  Patients with diabetic polyneuropathies.

          -  Any type of chronic diarrhoea or frequent diarrhoea (defined as &gt;5 loose stools per
             day).

          -  Faecal impaction and overflow diarrhoea.

          -  Male patients with clinically diagnosed prostatic hyperplasia.

          -  Clinically significant electrolyte abnormalities, e.g. clinically significant
             low/high potassium and low sodium.

          -  Presence of clinical symptomatic haemorrhoids (grade III and IV), anal fissures or
             anorectal fistulas.

          -  Less than 2 episodes of faecal incontinence (solids, liquid, gas or mucus) per week
             during the 4 week historical period prior to Visit 1 - Screening Visit.

          -  Participation in a clinical drug study during the 90 days preceding the initial dose
             in this study.

          -  Known history of allergy to methoxamine or any other ingredients of the
             Investigational Medicinal Product.

          -  Patients who, in the opinion of the Investigator, are unsuitable for participation in
             the study due to any dependencies, general medical conditions or significant illness
             within two weeks prior to randomisation.

          -  Use of any disallowed concomitant medication or other medication that the
             Investigator believes may affect the study including over-the-counter (OTC) products
             within 30 days prior to the Investigational Medicinal Product administration.

          -  A personal or family history of QTcf prolongation or sudden death.

          -  Patients taking Loperamide (2mg) &gt;8 tablets per day for faecal incontinence either
             alone or in combination with codeine phosphate and/or paracetamol (8/500mg).

          -  Patients using any device for the treatment of faecal incontinence.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent Siproudhis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Pontchaillou</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deborah J Jones, BSc(Hons)</last_name>
    <phone>+44189582</phone>
    <phone_ext>6636</phone_ext>
    <email>djones3@norgine.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Richard Ng Kwet Shing, MD</last_name>
    <phone>+44189545</phone>
    <phone_ext>3584</phone_ext>
    <email>rng@norgine.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fakultni Nemocnice BRNO</name>
      <address>
        <city>Brno</city>
        <zip>620 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel Weber</last_name>
      <email>p.weber@fnbrno.cz</email>
    </contact>
    <investigator>
      <last_name>Pavel Weber</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterologie S R O</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milan Siroky, Dr</last_name>
      <email>sirokydr@volnv.cz</email>
    </contact>
    <investigator>
      <last_name>Milan Siroky, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krajska Nemocnice Liberec</name>
      <address>
        <city>Liberec</city>
        <zip>130 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alena Jiroudkova</last_name>
      <email>alena.jiroudkova@nemlib.cz</email>
    </contact>
    <investigator>
      <last_name>Alena Jiroudkova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Na Bulovce, Gynekologicko-Porodnicka Klinika</name>
      <address>
        <city>Prague</city>
        <zip>180 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael M Halaska</last_name>
      <email>michael.halaska@if1.cuni.cz</email>
    </contact>
    <investigator>
      <last_name>Michael M Halaska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Egk S.R.O Sanatoriu&lt; Sv</name>
      <address>
        <city>Praha</city>
        <zip>130 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Jungwirthova</last_name>
      <email>m.hanuska@egk.cz</email>
    </contact>
    <investigator>
      <last_name>Anna Jungwirthova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakulni Nemocnice Kralovske</name>
      <address>
        <city>Praha</city>
        <zip>100 34</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duchac Vitezslav</last_name>
      <email>vitezslav.duchac@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Vitezslav Duchac</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice V Motole</name>
      <address>
        <city>Praha</city>
        <zip>150 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiri Hoch</last_name>
      <email>jiri.hoch@ifmotol.cuni.cz</email>
    </contact>
    <investigator>
      <last_name>Jiri Hoch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GEP Clinic S.R.O</name>
      <address>
        <city>Praha</city>
        <zip>130 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel P Drastich</last_name>
      <email>drastich@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Pavel P Drastich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Bordeaux - Hopital St Andre</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck Zerbib</last_name>
      <email>frank.zerbib@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Franck Zerbib</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Lyon Groupement Hospitalier Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francois Mion</last_name>
      <email>francois.mion@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Francois Mion</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Nantes - Hotel Dieu - Institut Des Maladies De L'Appareil Digestif (IMAD)</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Antoine Lehur</last_name>
      <email>paulantoine.lehur@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Paul Antoine Lehur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr Laurent Siproudhis</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laurent Siproudhis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Rouen - Hopital De Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Marie Pr Leroi</last_name>
      <email>anne-marie.leroi@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Anne-Marie Pr Leroi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zentrum Fur Darm-Und Beckenchirurgie</name>
      <address>
        <city>Berlin</city>
        <zip>14163</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland R Scherer</last_name>
      <email>r.scherer@waldfriede.de</email>
    </contact>
    <investigator>
      <last_name>Roland R Scherer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Martin-Luther-Krankenhaus</name>
      <address>
        <city>Berlin</city>
        <zip>14193</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hubert H Moennikes</last_name>
      <email>h.moennikes@mlk-berlin.de</email>
    </contact>
    <investigator>
      <last_name>Hubert H Moennikes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitats-Frauenklink</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim J Rom</last_name>
      <email>joachim.rom@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PMC Pannon Medical Center</name>
      <address>
        <city>Budapest</city>
        <zip>H-1136</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Schnabel</last_name>
      <email>schnabelrobert@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Robert Schnabel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinic for Outpatients, Szakrendelo Intezet</name>
      <address>
        <city>Budapest</city>
        <zip>H-1183</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tibor Kocsar</last_name>
    </contact>
    <investigator>
      <last_name>Tibor Kocsar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Debrecen, Medical and Health Science Center</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Istvan Altorjay</last_name>
    </contact>
    <investigator>
      <last_name>Istvan Altorjay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Szeged, Albert Szent-Gyorgyi Clinical Center, Faculty of Medicine</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andras Rosztoczy</last_name>
      <email>air@in1st.szote.u-szeged.hu</email>
    </contact>
    <investigator>
      <last_name>Andras Rosztoczy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Javorszky Odon Hopsital</name>
      <address>
        <city>Vac Argenti</city>
        <zip>H-2600</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tibor Szaloki</last_name>
      <email>szalokitdr@javorszky.hu</email>
    </contact>
    <investigator>
      <last_name>Tibor Szaloki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Csolnoky Ferenc Veszprem</name>
      <address>
        <city>Veszprem</city>
        <zip>H-8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Attila Nagy</last_name>
    </contact>
    <investigator>
      <last_name>Attila Nagy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chirurgia Gastroenterologica</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola De Nardi</last_name>
      <email>denardi.paola@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Paola De Nardi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Casa Di Cura San Pio X</name>
      <address>
        <city>Milano</city>
        <zip>20159</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonardo Lenisa</last_name>
      <email>leonardo_lenisa@lycos.com</email>
    </contact>
    <investigator>
      <last_name>Leonardo Lenisa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seconda Unita Operativa Di Chirurgia Generale</name>
      <address>
        <city>Pordenone</city>
        <zip>33170</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelo Stuto</last_name>
      <email>skaltro@mac.com</email>
    </contact>
    <investigator>
      <last_name>Angelo Stuto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unita Operativa Complessa Gastroenteroloogia A</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrico Corazziari</last_name>
      <email>enrico.corazziari@uniroma1.it</email>
    </contact>
    <investigator>
      <last_name>Enrico Corazziari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unita Operativa Complessa Patologia Chirurgica A Indirizzo Gastroenterologico</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Frascio</last_name>
      <email>mfrascio@unige.it</email>
    </contact>
    <investigator>
      <last_name>Marco Frascio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento Emergenza Urgenza</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filippo La Torre</last_name>
      <email>Filippo.latorre@uniroma1.it</email>
    </contact>
    <investigator>
      <last_name>Filippo La Torre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nzoz Vitamed</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-079</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michal Walczak</last_name>
      <email>m.walczak@wp.pl</email>
    </contact>
    <investigator>
      <last_name>Michal Walczak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General And Proctology Surgeon</name>
      <address>
        <city>Gdow</city>
        <zip>32-420</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr P Walega</last_name>
      <email>pwalega@mp.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne, Wyzszej Szkoly Informatycznej</name>
      <address>
        <city>Glowno</city>
        <zip>95-015</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Dziki</last_name>
      <email>trzcinskir@wp.pl</email>
    </contact>
    <investigator>
      <last_name>Adam Dziki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nzoz Mekmed S.C. Przychondnia Lekarska</name>
      <address>
        <city>Katowice</city>
        <zip>40-079</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henryke Mekle</last_name>
      <email>henryk.mekle@melmed.pl</email>
    </contact>
    <investigator>
      <last_name>Henryke Mekle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nzoz Mikomed</name>
      <address>
        <city>Lodz</city>
        <zip>94-238</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacek J Smigielski</last_name>
      <email>smiglo@mp.pl</email>
    </contact>
    <investigator>
      <last_name>Jacek J Smigielski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osrodek Badawczo - Leczniczy Zbigniew Zegota</name>
      <address>
        <city>Ostroda</city>
        <zip>14-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna J Piskorz-Wapinska</last_name>
      <email>solb@tlen.pl</email>
    </contact>
    <investigator>
      <last_name>Joanna J Piskorz-Wapinska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Endoskopia</name>
      <address>
        <city>Sopot</city>
        <zip>81-756</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek M Horynski</last_name>
      <email>badanie.kliniczne@wp.pl</email>
    </contact>
    <investigator>
      <last_name>Marek Horynski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lubelskie Centrum Diagnostyczne</name>
      <address>
        <city>Swidnik</city>
        <zip>21-040</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomasz T Blicharski</last_name>
      <email>blicharski@vp.pl</email>
    </contact>
    <investigator>
      <last_name>Tomasz T Blicharski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lecznica Prosen SMO Private Medical Health Care Centre</name>
      <address>
        <city>Warsaw</city>
        <zip>01-231</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maciej Kierzkiewicz</last_name>
      <email>ifurman@prosensmo.pl</email>
    </contact>
    <investigator>
      <last_name>Maciej Kierzkiewicz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ars Medica SC</name>
      <address>
        <city>Wroclaw</city>
        <zip>53-333</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Wozniak-Stolarska</last_name>
      <email>basiastolarska@interia.pl</email>
    </contact>
    <investigator>
      <last_name>Barbara Wozniak-Stolarska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic De Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria Lacima</last_name>
      <email>glacima@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Gloria Lacima</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Valle De Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eloy Espin Basany</last_name>
      <email>eespin@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Eloy Espin Basany</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USP, Hospital De Marbella</name>
      <address>
        <city>Malaga</city>
        <zip>29603</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Perona</last_name>
      <email>monica.perona@usphospitales.com</email>
    </contact>
    <investigator>
      <last_name>Monica Perona</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital De Mataro</name>
      <address>
        <city>Mataro</city>
        <zip>08304</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pere Clave</last_name>
      <email>pclave@csdm.cat</email>
    </contact>
    <investigator>
      <last_name>Pere Clave</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universtiaria Lozana Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico F Sopena</last_name>
      <email>fsopenab@medynet.com</email>
    </contact>
    <investigator>
      <last_name>Federico F Sopena</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pelvic Floor Centre</name>
      <address>
        <city>Malmo</city>
        <zip>205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Starck</last_name>
      <email>Marianne.starck@skane.se</email>
    </contact>
    <investigator>
      <last_name>Marianne Starck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kirurgiska Kliniken Universitetssjukhuset</name>
      <address>
        <city>Orebro</city>
        <zip>70362</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magnus V Andersson</last_name>
      <email>magnus.andersson@orebroll.se</email>
    </contact>
    <investigator>
      <last_name>Magnus V Andersson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Enheten For Nedre Abdominell Kirurgi</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulf Gunnarsson</last_name>
      <email>ulf.gunnarsson@kl.se</email>
    </contact>
    <investigator>
      <last_name>Ulf Gunnarsson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Surgical Sciences</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wilhelm Graf</last_name>
      <email>wilhelm.graf@akademiska.se</email>
    </contact>
    <investigator>
      <last_name>Wilhelm Graf</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Mark's Hospital</name>
      <address>
        <city>London</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolynne Vaizey</last_name>
      <email>cvaizey@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Carolynne Vaizey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anton Emmanuel</last_name>
      <email>a.emmanuel@ucl.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queens Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Maxwell-Armstrong</last_name>
      <email>charles.maxwell-armstrong@talk21.com</email>
    </contact>
    <investigator>
      <last_name>Charles Maxwell-Armstrong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nothern General Hopsital</name>
      <address>
        <city>Sheffield</city>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Brown</last_name>
      <email>steven.brown@sth.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Steven Brown</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 25, 2013</lastchanged_date>
  <firstreceived_date>August 1, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Faecal Incontinence</keyword>
  <keyword>Suppository</keyword>
  <keyword>Wexner score</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fecal Incontinence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methoxamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
